Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
11. September 2023 08:00 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics to Participate in Upcoming Investor Conferences
30. August 2023 08:00 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
28. August 2023 16:05 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
09. August 2023 16:03 ET
|
Pliant Therapeutics, Inc.
Initiation of Phase 2b BEACON-IPF trial of bexotegrast in patients with IPF INTEGRIS-PSC Phase 2a 12-week data of bexotegrast in patients with PSC expected in the third quarter of 2023 ...
Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis
09. August 2023 08:00 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics to Participate in Upcoming Investor Conferences
25. Juli 2023 08:00 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
23. Juni 2023 07:30 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
24. Mai 2023 08:00 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics to Participate in Upcoming Investor Events
10. Mai 2023 08:05 ET
|
Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
09. Mai 2023 16:02 ET
|
Pliant Therapeutics, Inc.
Positive long-term data from INTEGRIS-IPF 320 mg dose group at 24-weeks demonstrated bexotegrast was well tolerated with durable improvement shown across multiple measures INTEGRIS-PSC...